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Introduction 
Nanomedicine is a rapidly growing field in the aca-
demic as well as commercial arena. While some had 
predicted nanomedicine sales to reach $20.1 billion in 
2011,1 the actual growth was much more rapid, with 
the global nanomedicine market being valued at $53 
billion in 2009, and forecast to increase at an annual 
growth rate of 13.5% to reach more than $100 billion 
in 2014.2 In 2006, more than 130 nanotechnology-
based drugs and delivery systems had entered pre-
clinical, clinical, or commercial development.3 The 
European Medicines Agency (EMA) reviewed 18 mar-
keting authorization applications for nanomedicines 
in 2010.4 In 2011, 22 drugs that had been approved 
by the FDA, and 87 Phase I and Phase II clinical trials 
were listed in the U.S. National Institutes of Health 
(NIH) data base, www.clinicaltrials.gov.5 Although 
the fastest growing areas of nanomedicine are appli-
cations in medical imaging and diagnosis using con-
trast-enhancing agents, most nanomedicine research 
and commercialization is in the area of cancer drug 
therapy, including nano gold shells.
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In the short and medium term, the main use of 
nanoparticle medicinal products is to provide vec-
tors carrying active components or to deliver materi-
als that can be activated and/or detected at the site of 
interest. This includes reformulation of existing thera-
peutics as small particles to aid delivery — a strategy 
used in several products already marketed like Doxil™ 
and Abraxane™. However, most current work is in the 
area of third-generation vectors that combine a bio-
degradable core and a polymer envelope (PEG) with 
a membrane recognition ligand.6  While previous uses 
of nanomedicines have included using liposomes as 
passive vehicles for drug transport, active nanomate-
rials with complex properties and functions in drugs 
are not too far in the future. These include self-assem-
bling peptide nanofibers, scaffolds for tissue regen-
eration, sensors of biomarkers, artificial retinas, and 
chip-based nanolabs.7 
These developments hold the potential to provide 
immense benefits for disease treatment in the near 
future. At the same time, the novel technologies also 
raise safety and ethical concerns in human subjects 
research (HSR) that may challenge the existing sys-
tem of oversight. One aspect of HSR that has not 
received robust attention are concerns about occupa-
tional exposures of researchers and lab workers, and 
exposures of bystanders such as health care workers, 
family members, and caretakers during HSR using 
nanomaterials (“third-party” exposures). In principle, 
exposures can occur during the handling and admin-
istering of the pharmaceutical by the health care 
workers or the family members (if they are involved 
in drug administration). The high nanoparticle con-
tent of biological wastes excreted by research subjects 
also has been cited as a concern for potential exposure 
to bystanders and the environment.8 Laboratory con-
tainment and disposal practices, as well as excretion 
and shedding, can additionally release nanomaterials 
into the environment.
There are several stages that precede the clinical 
trial phase of nanomedicine research, including the 
production of the raw nanomaterials, synthesis of the 
pharmaceutical in a lab or manufacturing setting, and 
preclinical drug studies in animals and in vitro. Most 
of the somewhat limited exposure information that we 
have so far is associated with such production, synthe-
sis, and preclinical studies in industrial settings. Less 
is known about occupational exposures in the clinical 
trial phases and the post-marketing phase — both in 
terms of the types and magnitudes of the nanomate-
rial exposures as well as the types of workers who may 
be exposed. This paper provides a description of the 
types of potential nanomedicine exposures, the exist-
ing oversight framework for handling worker and 
third-party exposures, the deficiencies of that frame-
work in clinical and residential settings, and possible 
new approaches to oversight. 
Defining Nanomedicine 
Nanomedicine, nanotherapeutics, and nanodiagnostic 
techniques incorporate materials that are engineered 
at the nanometer scale to take advantage of novel and 
advantageous properties that become manifest at that 
scale. However, defining nanotechnology remains a 
matter of debate and controversy. Agencies and scien-
tific bodies have defined nanotechnology in a variety 
of ways that reflect the different aims and perspectives 
of the respective organizations. 
The U.S. National Nanotechnology Initiative 
(NNI) defines nanotechnology as “the understand-
ing and control of matter at dimensions between 
approximately 1 and 100 nanometers, where unique 
phenomena enable novel applications,”9 and this is 
often taken as the de facto definition. However, such 
a one-size-fits-all definition does not capture subtle 
yet significant features of nano-products. The nano-
components in nanomedicines include a great variety 
of materials and structures, some of which are passive 
with fixed functionality and others that are active with 
functionalities that are triggered or changed by inter-
nal or environmental stimuli.10 In many cases, advan-
tageous as well as potentially harmful functionality 
is not sharply confined to the size region between 1 
nm — 100 nm, leading to debate about the upper size 
limit of the nanoscale range. For instance, while some 
make the case for novel behavior becoming predomi-
nant below 30 nm,11 others note that novel biological 
interactions enabled by nanotherapeutics may occur 
at scales larger than 100 nm.12 The Food and Drug 
Administration’s (FDA) Center for Drug Evaluation 
Research (CDER) defines nanomaterials in its Man-
ual of Policies and Procedures (MAPP) as “any mate-
rial with at least one dimension smaller than 1,000 
nanometers.”13 More broadly, FDA has stated that the 
agency as a whole does not adhere to a specific defini-
tion of nanotechnology, but rather focuses on mate-
rial behavior. At the same time, OSHA14 and NIOSH15 
have used the 100 nm cutoff as the basis for defining 
nanomaterials. 
The considerable uncertainty over how size alone 
affects biological behavior suggests that purely size-
based definitions may be inappropriate for the over-
sight of nanomedicine, if indeed one can even prop-
erly identify a category of therapeutics by “nano” size. 
One of the authors of this article has argued that it 
might be more useful to have oversight triggered on 
the basis of an ensemble of relevant attributes of a 
product or material rather than a size-based defini-
Ramachandran, Howard, Maynard, and Philbert
858 journal of law, medicine & ethics
SYMPOSIUM
tion.16 This ongoing debate goes to the heart of what 
it means for a product to be labeled as “nano,” and 
whether such labeling should spur oversight beyond 
what exists for other entities for which there is already 
an assessment of potency, ability to cross barriers 
(e.g., hydrophobicity and ability to cross the barrier 
provided by gloves), and the degree to which one is 
exposed.  In other words, are the existing best prac-
tices for handling hazardous materials sufficient for 
nanomedicine products as well? We argue that while 
further research is needed to characterize the risks of 
exposure to nanomedicine products, a precautionary 
approach to managing exposures is warranted. 
Risks from Potential Exposure for Workers 
and Third Parties
The typical model for commercial innovation in nano-
medicine is one where discovery made in academic 
labs is transferred to small start-up companies that 
validate the concept and initiate the pre-clinical and 
Phase I clinical trials. Then large companies take over 
these start-ups for further development of the drugs 
or devices, Phase II and III clinical trials, and bring-
ing the drugs or devices to market. There are several 
stages that precede the clinical trial phase of nano-
medicine research, including the production of the 
raw nanomaterials and synthesis of the pharmaceuti-
cal in a lab or manufacturing setting. The issues sur-
rounding oversight and management of exposure and 
risk in such standard occupational settings have been 
described at length in the literature 17 and are not the 
focus of this paper. Instead, we focus primarily on the 
clinical trial phases.
In the United States, an investigational new drug 
(IND) must progress through several phases of test-
ing before approval can be granted for introducing the 
therapeutic into the market.18 Preclinical studies can 
involve in vitro tissue or in vivo animal pharmacology 
and toxicity tests for initial safety screening of the drug. 
Results of this phase determine whether permission is 
granted for proceeding with a Phase I trial. This phase 
usually involves a small number of subjects (20-100) 
and is used to establish a safe dosage range and iden-
tify side effects of the IND in human beings. Based on 
the results from this phase, the IND is then approved 
for Phase II trials, where the drug is given to a larger 
group of people (100-500) to see if it is effective and 
to further evaluate its safety. Based on these results, 
approval is granted for Phase III trials in large groups 
of people (1,000-3,000) to confirm its effectiveness, 
monitor side effects, compare it to commonly used 
treatments, and collect information that will allow the 
IND to be used safely.19 Based on the results from these 
three phases of clinical trials, the FDA approves the 
drug for marketing in the United States. Sometimes 
Phase IV trials or post-marketing studies are con-
ducted to obtain additional information including the 
drug’s risks, benefits, and optimal use.
In terms of risks not only to the patients undergoing 
an experimental treatment but also to the health care 
workers and third parties, the maximum risk during 
clinical trials is during Phase I. While preclinical stud-
ies in vitro and in animals do inform 
Phase I trials, they have significant 
limitations, especially in the context of 
nanomedicine. There are three broad 
reasons for this. 
First, key mechanisms for exposure 
processes and toxic effects of engineered 
nanomaterials remain poorly under-
stood. Uncertainties relate to questions 
such as: (a) How long do manufactured 
nanomaterials persist in the environ-
ment? (b) How stable are nanomaterials 
over time? (c) What is the effect of par-
ticle shape on their fate and transport? 
(d) What are likely routes of exposure 
(e.g., inhalation, dermal, ingestion, and ocular)? (e) 
What are the metrics by which exposure should be 
measured (e.g., particle mass, number of particles, or 
surface area concentration)? (f ) What are key mecha-
nisms of translocation to different parts of the body 
after nanomaterials enter the body? and (g) What are 
possible mechanisms of toxicity, including oxidative 
stress due to surface reactivity, presence of transition 
metals leading to intracellular calcium and gene acti-
vation, and intracellular transport of nanomaterials to 
the mitochondria?20 The EHS hazards and risks asso-
ciated with these different types of interventions and 
materials can further depend on the characteristics of 
the nanoparticles themselves (e.g., size, composition, 
and surface chemistry),21 the behaviors of the nanopar-
ticles in biological systems (e.g., protein adsorption, 
In terms of risks not only to the patients 
undergoing an experimental treatment but also 
to the health care workers and third parties, the 
maximum risk during clinical trials is during 
Phase I. While preclinical studies in vitro and 
in animals do inform Phase I trials, they have 
significant limitations, especially in the context 
of nanomedicine. 
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barrier penetration, cellular uptake, aggregation, deg-
radation, pathway signaling, and toxicity), and the 
route through which the nanoparticles are introduced 
into the body (e.g., oral ingestion, parenteral admin-
istration, topical application, and implantation).22 
For many types of nanomedicine applications the lit-
erature dealing with potential EHS risks is sparse. In 
assessing overall risk, both the exposure and hazard 
aspects of risk are poorly understood. 
Second, in vitro tests are used to evaluate the 
generic toxicity of substances and are primarily used as 
a screening tool as well as a guide to the proper selec-
tion of an appropriate animal model for in vivo test-
ing. Such in vitro tests are cost-effective and rapid in 
assessing toxicity end-points. However, studies to date 
have been somewhat contradictory in their assessment 
of the correlation between in vitro and in vivo tests.23 
While there is obviously a great need for relevant and 
accurate in vitro tests for nanotoxicity, some current 
methods for such testing have limitations. These tests 
were established to assess the toxicity of conventional 
chemicals, and in some cases over-estimate or under-
estimate the hazard of nanoparticles. Nanoparticle 
properties may cause interference with assay ingredi-
ents and detection systems, and cause artifacts in cyto-
toxicity studies. The properties causing interference 
include (a) high adsorption capacity that can cause 
the adsorption of nutrients and growth factors from 
culture media and is dependent on surface charge 
and hydrophobicity; (b) the light-absorptive nature of 
metallic properties that can affect cell viability read-
outs; (c) catalytic activity enhanced by the high surface 
area/mass ratios that can increase the production of 
reactive oxygen species and affect assays based on sub-
strate oxidation; and (d) magnetic properties that can 
affect production of free radicals.24 To ensure appropri-
ate interpretation of assay results and comparison with 
other evaluations, in vitro testing requires a complete 
characterization of nanoparticle properties using ref-
erence materials and validation of assay techniques. 
The health effects can also be extrapolated from 
studies performed on similar populations or due 
to exposure to similar agents to determine toxicity 
parameters that may not otherwise available. How-
ever, in the case of novel materials it may be difficult 
to find comparable populations or even comparable 
nanomaterials from which to estimate parameters, 
and uncertainty factors are typically required to 
account for the errors that are introduced during 
extrapolation.25) The clinical significance of the effects 
reported in the literature is unclear. Similarly, the 
long-term biological consequences of these particles 
in the body and the potential for unintended effects as 
well as immunological, inflammatory, or carcinogenic 
effects are also uncertain.26
Third, animal studies may not always be predic-
tive of effects in humans due to differences in biology 
and the well-known problems of extrapolating from 
animals to humans. Animal and in vitro studies are 
typically short-term (typically ~100 days) acute tox-
icity tests and do not address toxicity resulting from 
longer-term or chronic exposure.27 
The risk is somewhat decreased in Phase II trials 
because of the information gathered in Phase I. How-
ever, Phase I studies are also typically short-term in 
duration and do not address long-term effects that 
manifest over several years. Similarly, the risks to par-
ticipants, health care workers, and third-parties are 
not minimized or eliminated in Phase III trials. Even 
Phase III studies do not have the large number of sub-
jects needed to assess the risk of rare adverse events; 
it is recommended that Phase III trials should at least 
have 3000 subjects to be able to detect rare effects 
(defined as 1 case out of 1000) with some degree of 
confidence, and manufacturers should also conduct 
post-marketing (or Phase IV) studies.28 
The above discussion indicates that the risk picture 
in clinical trials is that of a pyramid where the highest 
risk is at the top (i.e., Phase I). The lower tiers of the 
pyramid represent the decreasing risk in successive 
phases, but with increasing numbers of subjects. 
The different tiers of clinical trials have different 
exposure potentials because they may most likely be 
conducted in different settings with varying degrees 
of exposure control and regulatory oversight: Phase I 
and II trials are most likely to be conducted in hospi-
tal or clinical settings with well-designed administra-
tive and engineering controls. For example, the acute 
side effects of existing nanoparticulate agents such as 
Doxil™ (e.g., complement activation) have been char-
acterized and dealt with through the usual preclinical 
and clinical trial evaluation methodologies. The expo-
sure risk exists at the points of delivery or handling 
where conventional exposure controls would likely 
suffice in hospital settings, although further studies 
need to be conducted. 
However, clinical trials are increasingly being con-
ducted at the residence of the patients for reasons of 
cost. Phase III and post-marketing studies, in particu-
lar, may be conducted in quasi-clinical as well as resi-
dential settings where exposure controls may be mini-
mal to non-existent. Exposures (e.g., in chemotherapy 
done at home by home health care nurses) would occur 
in settings that can be very variable and uncontrolled. 
While this may be true of exposures to nanomedicines, 
it is also true more generally of exposures to all types 
of therapies. Exposures in these settings have not been 
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studied in any depth and thus are poorly character-
ized. This is a frontier area in occupational health that 
requires further research. At the same, while the test-
ing of therapeutics in such settings has become more 
frequent, there is a need for precaution and diligence 
in managing exposures effectively. 
Oversight Regime 
Health care is delivered in public and private hospi-
tals; nursing and residential care facilities; offices of 
physicians, dentists, and other health care practitio-
ners; home health care services; outpatient care cen-
ters and other ambulatory health care services; and 
medical and diagnostic laboratories. In all of these 
work settings, exposure to pharmaceuticals may 
occur. Health care is the largest sector in the American 
economy, employing nearly 12% of the total employed 
labor force in 2010, and has a high incidence of occu-
pational injury and illness.29 In 2004, the incidence 
of occupational injury and illness in hospitals was 8.7 
cases per 100 full-time workers, and in nursing care 
facilities was 10.1 cases per 100 full-time workers, 
compared with the average of 5.0 for private industry 
overall.30 Health care workers are exposed to a greater 
range of significant workplace hazards than workers 
in any other sector,31 including potential exposure to 
airborne and bloodborne infectious disease, sharps 
injuries, and other dangers. The occupational risks 
faced by this category of workers have not been well 
characterized for all kinds of hazards, including those 
relating to nanomedicine. 
The plethora of settings in which nanomedicine 
research and clinical and post-marketing trials occur 
fall under several oversight and regulatory regimes. 
Research and Clinical Laboratories 
The occupational safety of laboratory workers and 
scientists falls under the purview of OSHA. Under 
this framework, research and academic institu-
tions have laboratory safety committees responsible 
for ensuring the adequacy of safety training and the 
compliance of lab procedures with OSHA (29 C.F.R. 
part 1910). However, OSHA has no nanotechnology-
specific standards; instead, only general OSHA stan-
dards are applicable. These include the standards for 
personal protective equipment (§1910.132), eye and 
face protection (§1910.133), respiratory protection 
(§1910.134), hand protection (§1910.138), sanitation 
(§1910.141), hazard communication (§1910.1200), 
occupational exposure to hazardous chemicals in lab-
oratories (§1910.1450), and some substance-specific 
standards (e.g., §1910.1027, Cadmium). However, 
these generic standards are applicable to a wide range 
of chemical hazards and do not address nano-specific 
hazards. 
Additional oversight is provided by the Centers 
for Disease Control and Prevention (CDC) and NIH 
through their joint Biosafety in Microbiological and 
Biomedical Laboratories (BMBL) manual that pro-
vides guidance on laboratory practices, safety equip-
ment, and facility design, as well as information on spe-
cific microbiological agents of concern to lab worker 
safety.32 While this oversight applies to research with 
microbiological agents, the manual’s standards may 
not be adequate in the case of active nanotherapeutics 
that straddle the boundary between chemical and bio-
logical agents. If the medications were administered 
to the patient by IV, injection or mouth the OSHA 
Blood Borne Pathogens standard would apply and 
would address issues such as PPE, and training.
NIOSH is already involved in nanotechnology-
related occupational risk and safety assessment. This 
agency has produced a number of guidance docu-
ments on safe handling and monitoring of nanomate-
rials in the workplace,33 some of which are specific to 
the use of nanomaterials in laboratories.
Except for a very few substances, there are no estab-
lished exposure limits for many nanomaterials. Even 
the few materials with exposure limits are not really 
relevant to nanomedicine applications. This, by itself, 
is not a cause for undue concern in terms of exposure 
management. There are many “hazardous drugs”34 
without exposure limits that have effective exposure 
management in the pharmaceutical industry. In the 
absence of exposure limits (which can also serve as 
performance standards for evaluating the adequacy 
Health care workers are exposed to a greater range of significant workplace 
hazards than workers in any other sector, including potential exposure to 
airborne and bloodborne infectious disease, sharps injuries, and other dangers. 
The occupational risks faced by this category of workers have not been well 
characterized for all kinds of hazards, including those relating to nanomedicine. 
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of exposure controls), we may need to rely on process 
standards (i.e., directives to implement specific con-
trol measures in specific situations). However, such 
process standards have not been validated for nano-
medicines, so we cannot be sure whether the controls 
actually protect workers to the extent necessary to 
safeguard health. Many institutions have developed 
in-house guidelines for handling nanomaterials and 
for exposure management. For example, university 
Environmental Health and Safety departments typi-
cally have procedures for record-keeping and inven-
tory, labeling and packaging, storage, engineering 
controls, work practices, engineering controls, use 
of personal protective equipment, clean-up proce-
dures, and waste disposal. These guidelines tend to 
be generic with a presumption of conservatism, i.e., 
implementation of such procedures will ensure that 
exposures are de minimis and below acceptable levels. 
However, efforts at validation of these guidelines are 
in their infancy. For example, the degree of clean-up 
after a chemical spill is generally unspecified; in the 
case of a spill involving nanomaterials, there are fur-
ther difficulties with difficulties detecting small quan-
tities of nanomaterials.
NIOSH has developed a series of publications that 
provide guidelines and universal precautions for safe 
handling of antineoplastic and hazardous drugs. 
These documents make no attempt to perform drug 
risk assessments or propose exposure limits. Instead, 
the recommendations focus on the need to implement 
necessary administrative and engineering controls, 
assure that workers use sound procedures for han-
dling hazardous drugs and proper protective equip-
ment, and perform medical surveillance.35
The pharmaceutical industry has developed per-
formance-based exposure-control methods based on 
performance-based exposure-control limits.36 These 
methods are routinely validated using air and surface 
monitoring.37 The level of control depends on the 
hazard PB-ECL category, and so does the degree of 
monitoring. Such approaches based on hazard bands 
can be adapted for application to the case of nano-
therapeutics in the manufacturing environment. 
In health care environments, one approach would 
be to characterize nanotherapeutics as “hazardous 
drugs”38 that require special monitoring and control. 
Inhalation and surface sampling techniques can be 
used to characterize exposures of health care workers 
along with medical surveillance and biomonitoring.39 
One of the main bottlenecks to such approaches in 
manufacturing and health care settings is the dearth 
of validated analytical methods for detection and 
quantification of nanomaterials, especially in small 
quantities. Secondly, as mentioned in previous sec-
tions, both the hazard and the proper metric for 
quantifying many nanomaterial exposures are poorly 
understood. 
Home Health Care Settings 
Both short-term and longer-term clinical trials increas-
ingly occur in residential settings.40 It is likely that 
Phase III clinical trials and post-marketing studies for 
nanomedicines, as well as regular treatment especially 
for cancer may occur in residential environments 
using home health care providers and family members 
of patients to administer the pharmaceuticals. 
Home health care is the fastest growing sector of the 
health care industry.41 This is partly due to economic 
forces that are reducing hospital stays and partly due 
to the kinds of chronic care that patients require in 
the home. Increasingly, sophisticated medical devices 
and treatments are being introduced into the home. 
The workers in this sector include registered nurses, 
home health aides, attendants, and personal care 
workers. Home health aides provide basic nursing ser-
vices under medical direction, although without direct 
supervision. These services include checking patients’ 
vital signs, changing dressings, administering medi-
cations, and assisting with use of medical equipment, 
in addition to bathing and grooming, dressing and 
feeding. Thus, the scope of home care includes every-
thing from assisting with daily activities to more com-
plex care required by chronically ill or post-surgical 
patients such as dialysis, chemotherapy, and respira-
tory and infusion procedures.42 
Despite the increasing importance of this sector, 
the health hazards faced by this population of work-
ers are poorly characterized. Since the home is not 
designed as a health care workplace, a number of haz-
ards emerge in such environments for the health care 
workers. They face an increased incidence of injury 
compared to other health care workers.43 Common 
household hazards reported in the few extant studies 
include unsanitary conditions and inadequate disin-
fection, mismanagement of medical wastes includ-
ing biomedical wastes, sharps and needlesticks, and 
infections during home infusion therapies.44 These 
are significant concerns in relation to potential expo-
sure of home health care workers and family members 
to nanotherapeutics being administered in uncon-
trolled home settings. However, this is true of expo-
sures to other types of therapeutics as well. There is 
poor oversight for such workers. OSHA’s oversight of 
such workplaces requires improvement. Much more 
attention needs to be paid to the hazards faced by this 
group of workers.  
The employers of home care workers are mostly 
free-standing proprietary agencies, hospital-based 
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agencies, non-profit public health agencies, or private 
agencies.45 In addition, there is an informal, unlicensed 
home care network whose extent is not well known. In 
theory, if the home health worker administering the 
drugs is employed by a company or hospital then she/
he is covered under OSHA regulations. If the medica-
tions were administered to the patient by IV, injection, 
or mouth the OSHA Blood Borne Pathogens standard 
(29 CFR* 1910.1030) would apply and would address 
issues such as PPE, and training. While the employer 
of the workers may be responsible for the health and 
safety of the workers, they may not have complete con-
trol over exposures in the home. 
However, they can provide training to their workers 
(e.g., for compliance with the bloodborne pathogens 
standard) in safe practices. NIOSH has conducted a 
review of occupational hazards faced by home health 
care workers that recommends management and pre-
vention strategies to reduce illnesses from such haz-
ards. The training of home care workers is variable 
and often inadequate.46 Increased funding for the 
agencies employing these workers for training pur-
poses, reimbursement for training time, and funding 
for appropriate safety equipment and supplies are 
necessary steps.47
Workers facing illnesses due to exposure to nano-
medicine hazards would be eligible for worker’s com-
pensation. However, worker’s compensation insur-
ance requirements for employers vary from state to 
state. Thus, while Minnesota and Michigan require 
all employers to provide insurance coverage to all 
employees without exemptions, Alabama does not 
regulate worker’s compensation requirements for 
employers, and other states provide employers with 
varying exemptions.48 
Oversight that applies to family members who may 
be exposed to nanotherapeutics during home care is 
beyond the scope of this article. However, illnesses 
resulting from such exposures might be redressed 
through home owners insurance covering injury at 
the residence, product liability lawsuits, and tort suits 
claiming hospital negligence. 
Conclusions
The rapid developments in nanomedicine research 
raise significant questions relating to the protection 
of researchers, lab workers, and health care workers 
engaged in clinical trials involving nanotherapeutics. 
The hazards from such exposures are poorly under-
stood, as is true in the case of nanomaterial exposures 
more generally. There are several challenges to man-
aging such exposures. 
First, the very definition of what products need to 
be regulated varies among agencies such as the FDA, 
OSHA, and NIOSH; this may result in some nano-
therapeutics falling through the regulatory cracks. 
At the same time, commentary has suggested that 
“nano” not be defined in terms of size and instead 
be replaced with definitions based on an ensemble 
of relevant attributes of a product or material. The 
effects of any such definitional changes on oversight 
and exposure management need to be studied thor-
oughly. Second, the diverse sites in which clinical 
trials can occur can potentially lead to varying over-
sight bodies at federal, state, and local levels. While 
laboratory and clinical settings may come under 
OSHA purview for chemical hazards, this agency’s 
nanotechnology-related standards are generic. CDC/
NIH oversight for microbiological hazards by means 
of the BMBL manual will pose challenges for nano-
medicine, as active nanopharmaceuticals blur the 
distinction between biological and chemical agents. 
The pharmaceutical industry has been proactive in 
developing performance-based exposure controls 
and limits, and such approaches will most likely be 
applied for nanotherapeutics as well. However, just 
as in the case for conventional “hazardous drugs,” 
such exposure controls for nanomedicines will need 
to be validated. 
It may turn out that nanomedicine therapies do not 
represent fundamentally different categories of haz-
ards to third parties. However, given the current state 
of knowledge regarding health risks from such expo-
sures, a more precautionary approach seems advis-
able. Even if we assume that the health risks posed by 
nanomedicines are not very different, nanomedicines 
pose new challenges for monitoring, and therefore, for 
the validation of control measures. Further research 
is needed to determine whether the exposure controls 
for nanomedicines need to be different than those for 
conventional therapies or drugs that are defined as 
“hazardous.”
Home health care workers are a sector of the health 
workforce raising particularly acute concerns. These 
employees are typically inadequately trained in safety 
procedures and work in residences that usually have 
few or no exposure controls, with employers hav-
ing little control over workplace conditions. There is 
inadequate oversight of occupational hazards in gen-
eral for such workers, and this will most likely be true 
for nano-drugs as well. This sector of the workforce 
requires more extensive study and health surveil-
lance as they face novel technologies with unknown 
hazards. 
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